Nubeqa (darolutamide) is a brand-name oral tablet prescribed for certain types of prostate cancer in adults. As with other drugs, darolutamide may cause side effects, such as fatigue, nausea, and rash ...

Nubeqa (darolutamide) is a prescription drug that’s used to treat certain types of prostate cancer in adults. Nubeqa comes as an oral tablet. Nubeqa contains the active ingredient darolutamide. (An ...

Adding Nubeqa to androgen deprivation therapy improved radiographic progression-free survival in patients with metastatic hormone-sensitive prostate cancer. The combination of Nubeqa (darolutamide) ...

Patients treated with Nubeqa were less likely to develop disease metastasis or discontinue treatment 6 to 18 months after ARI course start compared to Xtandi or Erleada, according to data presented at ...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for the oral ...

These results build on existing data from the ARASENS trial, which show that NUBEQA plus ADT and docetaxel compared to ADT and docetaxel significantly reduces the risk of death in patients with mHSPC ...

Bayer has won a key FDA approval to extend the use of its prostate cancer therapy Nubeqa, as it tries to claim market share from rival drugs and fulfil its aim of building the drug into a €3 billion ...

Bayer has claimed a second pivotal trial win for its blockbuster-to-be androgen receptor inhibitor Nubeqa, looking to reach the entire space of metastatic hormone-sensitive prostate cancer (mHSPC).

WHIPPANY, N.J.-- (BUSINESS WIRE)--A new ad hoc analysis from the Phase III ARAMIS trial showed 97.2% of men with non-metastatic castration-resistant prostate cancer (nmCRPC) taking NUBEQA ® ...

Phase II ARACOG (AFT-47) head-to-head trial met its primary endpoint, with patients treated with NUBEQA® (darolutamide) showing a decline in maximally changed cognitive domain (MCCD) by 24 weeks, with ...